Patents by Inventor Lujia PENG

Lujia PENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220363731
    Abstract: By introducing at least one cysteine residue based on wild-type IL-2, the binding plane of the IL-2 derivative and ? receptor subunit is partially or completely blocked, while the affinity of the IL-2 derivative to the complex of ? and ? receptor subunits is basically retained. A complex includes an IL-2 derivative, which is introduced with a third cysteine residue based on wild-type IL-2; and a blocking module, which has or is introduced with a fourth cysteine residue. The third cysteine residue on the IL-2 derivative and the fourth cysteine residue on the blocking module are capable of forming an intermolecular disulfide bond, thereby forming a complex of the IL-2 derivative and the blocking module. The binding plane of the IL-2 derivative and ? receptor subunit is partially or completely blocked, while the affinity of the IL-2 derivative to the complex of ? and ? receptor subunits is basically retained.
    Type: Application
    Filed: January 7, 2020
    Publication date: November 17, 2022
    Applicant: LETO LABORATORIES CO., LTD
    Inventors: Yao ZHAO, Lujia PENG, Jianyun GUO, Xiaoting ZHU, Jianjun ZHANG, Tingting WEI, Huijie LIU, Qian ZHENG, Jishu WANG, Wei ZHANG
  • Publication number: 20220348624
    Abstract: The amino acid sequence of the present IL-15 analog includes the amino acid sequence of IL-15 and an amino acid sequence including at least one positively charged amino acid added to the C-terminal of the amino acid sequence of IL-15. The present IL-15 analog is highly expressed in Escherichia Coli, wherein the expression level is about 20-fold higher than that of the wild-type IL-15, and there is no significant difference in cell activity in vitro. In addition, a conjugate of the IL-15 analog improves the half-life and the long-term efficacy of the IL-15 analog by coupling with the fatty acid chain. These improvements lay a foundation for the industrialization of IL-15 protein drugs.
    Type: Application
    Filed: September 24, 2020
    Publication date: November 3, 2022
    Applicant: LETO LABORATORIES CO., LTD
    Inventors: Yao ZHAO, Jianjun ZHANG, Xiaoting ZHU, Yanling XU, Lujia PENG, Jishu WANG, Wei ZHANG